In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Top Device Stories of 2009: A Year of Economic Revival and Regulatory Risk

Executive Summary

2009 was the most difficult year the device industry faced in a long time, particularly given the boom years that preceded it. Public and private investors grew nervous and sat on the sidelines, as did most corporate acquirers. As a result, most start-ups found it difficult to raise money and VCs were frustrated by the poor returns being generated, especially compared with the previously frothy climate. The silver lining may be that there are signs that the economic environment may be improving and that corporate acquirers will continue to pay a premium for the right deal. Overhanging all of this, however, is the specter of health care reform and its impact on the device industry, whether through a device tax, comparative effectiveness or some unanticipated other result, meaning the industry is far from out of the woods.
Advertisement

Related Content

Device Tax, Health Reform Close To Reality As Conference Committee Meets
Top Device Stories of the Decade
On-Q-ity Inc.
The Future of Drug-Eluting Stents Part I: Novel Next-Generation Designs
Noninvasive Prenatal Diagnostics: How Much Closer to Reality?
Ardian: Succeeding Where Drugs Fail--Treating Hypertension in the Cath Lab
Schultz Exits: Pressures From Inside And Out Catch Up With CDRH Director
Sequenom's Failure Highlights an Underappreciated Risk of Biotech Investing
Health Care Reforms Target Medical Devices
Neuronetics' FDA Nod Opens Doors to New CNS Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel